Program
tarlatamab
Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms · Prostatic Neoplasms, led by Amgen.
Furthest: phase 3, since Feb 7, 202313 company-led studies, 12 open or runningNext primary completion: Apr 24, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 1312 open or running | phase 3since Feb 7, 2023 | Oct 5, 2017 | Apr 24, 2027phase 1 · NCT06598306 |
Also a collaborator on its studies: AstraZeneca and BeOne Medicines.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 5, 2017.
- Sep 17, 2021Phase 2 study in Small Cell Lung CarcinomaNCT05060016 · 222 enrolled · United States, Austria, Belgium and more
- Feb 7, 2023Phase 3 study in Small Cell Lung CarcinomaNCT05740566 · 509 enrolled · United States, Argentina, Australia and more
- Oct 31, 2023Phase 3 study in Small Cell Lung CarcinomaNCT06117774 · 404 enrolled · United States, Argentina, Australia and more
- Jan 8, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06211036 · 563 enrolled · United States, Argentina, Australia and more
- Jul 9, 2024Phase 2 study in NeoplasmsNCT06502977 · 32 enrolled · China
- Sep 13, 2024Phase 1 study in Small Cell Lung CarcinomaNCT06598306 · 220 planned · United States, Australia, Belgium and more
- Dec 17, 2024Phase 2 study in Small Cell Lung CarcinomaNCT06745323 · 252 enrolled · United States, Argentina, Australia and more
- Mar 21, 2025Phase 1 study in Small Cell Lung CarcinomaNCT06898957 · 29 enrolled · United States, Canada, China and more
- May 27, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07005128 · 350 enrolled · United States, Argentina, Australia and more
- Apr 9, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07531095 · 160 planned · United States, Australia, Belgium and more
- Aug 12, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07778316 · 400 planned · United States, Australia, China and more
- Oct 6, 2026Primary completion moved from 2029-05-10 to 2029-08-10Date moved laterphase 2 · +3 months · NCT06745323
- Nov 4, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 1 · +12 months · NCT03319940
- Nov 6, 2026Primary completion moved from 2027-07-05 to 2030-04-02Date moved laterphase 3 · +33 months · NCT06211036
Ahead
- Apr 24, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06598306
- Sep 24, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07778316
- Dec 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT05060016
- Dec 31, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT03319940
TargetBeta
“A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07778316Small Cell Lung Carcinoma · United States, Australia, China and more | 3 | Recruiting | Sep 24, 2027 | 400 |
| NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | May 21, 2028 | 160 |
| NCT07005128Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 4, 2029 | 350 |
| NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more | 1 | Active, not recruiting | Jun 23, 2031 | 29 |
| NCT06745323Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 10, 2029 | 252 |
| NCT06598306Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | Apr 24, 2027 | 220 |
| NCT06502977Neoplasms · China | 2 | Active, not recruiting | Mar 28, 2025 | 32 |
| NCT06211036Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 2, 2030 | 563 |
| NCT06117774Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 20, 2030 | 404 |
| NCT05740566Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 29, 2025 | 509 |
| NCT05060016Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 2 | Active, not recruiting | Dec 30, 2027 | 222 |
| NCT04702737Neuroendocrine Prostate Cancer · United States, Australia, Austria and more | 1 | Completed | Jul 22, 2024 | 41 |
| NCT03319940Small Cell Lung Carcinoma · United States, Australia, Austria and more | 1 | Active, not recruiting | Dec 31, 2027 | 269 |
How it is read
Names in the registry
- “Tarlatamab”, 13 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.